DPP4/CD32b/NF-κB Circuit: A Novel Druggable Target for Inhibiting CRP-Driven Diabetic Nephropathy

C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus

Aruna D. Pradhan · JAMA · 2001 · 4.4K citations

Veterinary Medicine, Immunology, Disease Prevention +12

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Carolyn F. Deacon, Anders H. Johnsen, Jens J. Holst · The Journal of Clinical Endocrinology & Metabolism · 1995 · 757 citations

Life Sciences, Biochemistry, Endocrinology +16

C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice

Antoni Paul, Kerry W.S. Ko, Lan Li et al. · Circulation · 2004 · 379 citations

Life Sciences, Molecular Biology, Pathobiology +17

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

Keizo Kanasaki, Sen Shi, Megumi Kanasaki et al. · Diabetes · 2014 · 368 citations · Full text

Medicine, Nephrology, Pharmacology +17

Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria<subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>

Ian H. de Boer · Archives of Internal Medicine · 2011 · 348 citations · Full text

Medicine, Internal Medicine, Nephrology +15